A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

← catalyst calendar

NCT05685173 · readout in 912 d

Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

107estimated

Sites

Countries

France, Netherlands, Spain +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-04-20

actual

When the study began enrolling

Primary completion

2029-02-16

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-01-13

estimated

The whole study's end, after follow-up

First posted

2023-01-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-19

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

B-cell Non-Hodgkins Lymphoma (B-NHL)

Interventions

Drug: Odronextamab — also filed as REGN1979, Ordspono™
Drug: REGN5837

Primary outcomes

what the primary-completion date above is the date OF

Incidence of Dose Limiting Toxicities (DLTs) of REGN5837 in combination with odronextamab

measured From Cycle 2, Day 1 to Cycle 2, Day 21 (each induction cycle is 21 days)

Incidence of Treatment-Emergent Adverse Events (TEAEs) of REGN5837 in combination with odronextamab

measured Up to approximatively 5 years

Severity of TEAEs of REGN5837 in combination with odronextamab

measured Up to approximatively 5 years

Incidence of Adverse Events of Special Interest (AESIs) of REGN5837 in combination with odronextamab

measured Up to approximatively 5 years

Severity of AESIs of REGN5837 in combination with odronextamab

measured Up to approximatively 5 years

Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed